(1S,3R)-(+)-3-hydroxycyclopentyl acetate | 149342-58-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (1S,3R)-(+)-3-hydroxycyclopentyl acetate
• 英文别名: (1S,3R)-3-Hydroxycyclopentyl acetate；[(1S,3R)-3-hydroxycyclopentyl] acetate
• CAS: 149342-58-5
• 化学式: C₇H₁₂O₃
• 分子量: 144.17
• InChiKey: BWFGXNSNXSWGQA-RQJHMYQMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (1S,3R)-(+)-3-hydroxycyclopentyl acetate 在 咪唑 、 copper(l) cyanide 、 三苯基膦 、 sodium hydroxide 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 7.0h， 生成 C₁₄H₂₈OSi
  参考文献：
  名称：

  2-吡啶磺酰氧基离去基团与格氏试剂在仲烷基碳上快速铜催化的偶联反应中的应用

  摘要：

  铜催化的2-吡啶磺酸盐与格利雅试剂的偶联反应研究表明，与催化型Cu（OTf）2的反应在不到40分钟的时间内完成。结果与以前的CuI催化的甲苯磺酸盐在添加剂（LiOMe和TMEDA）存在下12-24小时的反应结果不同。结果表明，离去基团与试剂的优选配位促进了反应。成功的试剂是MeMgCl和其他RMgX。建立了完全反演。

  DOI：

  10.1021/acs.orglett.9b00976
• 作为产物：
  描述：

  Cis-3,5-二乙酰氧基-1-环戊烯 在 palladium on activated charcoal sodium dihydrogenphosphate 、 sodium azide 、 Electrophorus electricus acetylcholinesterase 、 氢气 作用下， 以 乙醇 为溶剂， 反应 2.0h， 生成 (1S,3R)-(+)-3-hydroxycyclopentyl acetate
  参考文献：
  名称：

  Chiral induction in cyclopentyl-derived 1,3-meso-diesters: enantioselective hydrolyses with electric eel acetylcholinesterase

  摘要：

  Eight 1,3-meso-diesters derived from a common cyclopentyl backbone were exposed to the hydrolase enzyme acetylcholinesterase from Electrophorus electricus. All eight compounds were hydrolyzed by the enzyme. The overall enantioselectivities were quite high, and the resulting e.e.s were generally >90%. The absolute configurations of the product monoesters were determined through stereochemical correlation. These data revealed that the preferred site for enzymatic hydrolysis in seven of the substrates was the pro-S ester function, with pro-R cleavage detected in the eighth. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(99)00236-0

文献信息

• [EN] SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS<br/>[FR] DÉRIVÉS DE PYRIDINE ET PYRIMIDINE SUBSTITUÉES ET LEUR UTILISATION DANS LE TRAITEMENT D'INFECTIONS VIRALES
  申请人：SCHERING CORP

  公开号：WO2010022121A1

  公开（公告）日：2010-02-25

  The present invention provides compounds of Formula (I): and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein wherein each of R, R1, X, Y, Z, R2, R3, R4, R5, R6, R7, R8, R9, R18, R19 and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders.

  本发明提供了式(I)的化合物：以及所述化合物的互变异构体、同分异构体和酯，以及所述化合物的药学上可接受的盐、溶剂化合物和前药，其中R、R1、X、Y、Z、R2、R3、R4、R5、R6、R7、R8、R9、R18、R19和n中的每个均独立选择并如本文所定义。还提供了包含这些化合物的组合物。本发明的化合物作为HCV的抑制剂是有效的，并且在治疗或预防病毒感染和与病毒相关的疾病或紊乱方面，单独或与其他治疗剂一起使用是有用的。
• [EN] 7-, 8-, and 10-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE<br/>[FR] DÉRIVÉS D'AMINO TRIAZOLO QUINAZOLINE À SUBSTITUTION EN POSITIONS 7, 8 ET 10 UTILISÉS EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE L'ADÉNOSINE, COMPOSITIONS PHARMACEUTIQUES ET LEUR UTILISATION
  申请人：MERCK SHARP & DOHME

  公开号：WO2020112706A1

  公开（公告）日：2020-06-04

  In its many embodiments, the present invention provides certain 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives of Formula (I): or a pharmaceutically acceptable salt thereof, wherein ring A, R1, R2, and R4 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutic agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and their use in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

  在其多种实施方式中，本发明提供了某些7-、8-和10-取代氨基三唑喹唑啉衍生物的化合物（I）的制备方法和用途，或其药学上可接受的盐，其中环A、R1、R2和R4如本文所定义，包括一种或多种这样的化合物的药物组合物（单独使用和与一种或多种其他治疗剂联合使用），以及其制备和用途的方法，单独使用和与其他治疗剂联合使用，作为A2a和/或A2b受体的拮抗剂，并且它们在治疗由腺苷A2a受体和/或腺苷A2b受体至少部分介导的各种疾病、症状或紊乱中的用途。
• Carbocyclic Nucleosides as Inhibitors of Human Tumor Necrosis Factor-α Production:  Effects of the Stereoisomers of (3-Hydroxycyclopentyl)adenines
  作者：David R. Borcherding、Norton P. Peet、H. Randall Munson、Hao Zhang、Paul F. Hoffman、Terry L. Bowlin、Carl K. Edwards

  DOI：10.1021/jm950906t

  日期：1996.1.1

  A series of four structurally related carbocyclic nucleosides (6a, 6b, 10a, and 10b) were synthesized and evaluated for their ability to inhibit tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), and interleukin-6 (IL-6) production from human primary macrophages. These compounds had little effect on the production of IL-1 beta and IL-6. It was determined that compound 10a was

  合成了一系列四个结构相关的碳环核苷（6a，6b，10a和10b），并评估了它们抑制肿瘤坏死因子-α（TNF-α），白介素-1β（IL-1 beta）和从人类原代巨噬细胞中产生白介素6（IL-6）。这些化合物对IL-1β和IL-6的产生几乎没有影响。已确定化合物10a是最有效的TNF-α抑制剂（IC50 = 10 microM），与其对映异构体10b或其非对映异构体6a和6b相比，活性高2至5倍。此外，还测试了这些化合物保护小鼠免受脂多糖（LPS）和D-半乳糖胺（D-Gal）致命攻击的能力。
• Trans cyclopentanyl purine analogs useful as immunosuppressants
  申请人：Hoechst Marion Roussel, Inc.

  公开号：US05723466A1

  公开（公告）日：1998-03-03

  This invention relates to Trans cyclopentanyl purine analogs of the formula (1) ##STR1## wherein the substituent in the 3-position on the cyclopentanyl ring is in the Trans configuration relative to the bicyclic substituent, Y.sub.3, Y.sub.5 and Y.sub.9 are each nitrogen and Y.sub.7 and Y.sub.8 are a CH group, R is a C.sub.1 -C.sub.7 alkyl acyl or aryl acyl, Q is NH.sub.2, halogen or hydrogen, Z is hydrogen, halogen, or NH.sub.2 ; or a pharmaceutically-acceptable salt thereof, and to their use as immunosuppressants.

  本发明涉及公式（1）的Trans环戊酰基嘌呤类似物 ##STR1## 其中，环戊酰基上的3位取代基与双环取代基Y.sub.3，Y.sub.5和Y.sub.9相对处于Trans构型，Y.sub.7和Y.sub.8为CH基，R为C.sub.1-C.sub.7烷酰基或芳基酰基，Q为NH.sub.2，卤素或氢，Z为氢，卤素或NH.sub.2；或其药学上可接受的盐，并用作免疫抑制剂。
• Organic Compounds
  申请人：Fairhurst Robin Alec

  公开号：US20100190784A1

  公开（公告）日：2010-07-29

  A compound of formula (I), or stereoisomers or pharmaceutically acceptable salts thereof, wherein, R 1a , R 1b , R 2a , R 2b , U 1 , U 2 , X 1 , X 2 and L are as defined herein.

  化合物的式子（I），或其立体异构体或药学上可接受的盐，其中，R1a，R1b，R2a，R2b，U1，U2，X1，X2和L的定义如下。